These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16514573)

  • 1. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
    Adam B; Liebregts T; Holtmann G
    Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
    [No Abstract]   [Full Text] [Related]  

  • 2. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
    Kruis W; Fric P; Pokrotnieks J; Lukás M; Fixa B; Kascák M; Kamm MA; Weismueller J; Beglinger C; Stolte M; Wolff C; Schulze J
    Gut; 2004 Nov; 53(11):1617-23. PubMed ID: 15479682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
    Folwaczny C
    Z Gastroenterol; 2000 Jun; 38(6):547-50. PubMed ID: 10923365
    [No Abstract]   [Full Text] [Related]  

  • 4. [Probiotics in chronic inflammatory bowel disease].
    Böhm S; Kruis W
    MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
    Henker J; Müller S; Laass MW; Schreiner A; Schulze J
    Z Gastroenterol; 2008 Sep; 46(9):874-5. PubMed ID: 18810672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
    Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
    Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
    Zocco MA; dal Verme LZ; Cremonini F; Piscaglia AC; Nista EC; Candelli M; Novi M; Rigante D; Cazzato IA; Ojetti V; Armuzzi A; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1567-74. PubMed ID: 16696804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
    Kruis W; Schütz E; Fric P; Fixa B; Judmaier G; Stolte M
    Aliment Pharmacol Ther; 1997 Oct; 11(5):853-8. PubMed ID: 9354192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
    Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ulcerative colitis. Complementary therapies].
    Matthes H; Moser G; Jantschek G
    Z Gastroenterol; 2004 Sep; 42(9):1031-2. PubMed ID: 15455282
    [No Abstract]   [Full Text] [Related]  

  • 13. VSL#3 and remission in active ulcerative colitis: larger studies required.
    Jackson EL; Hamlin PJ; Ford AC
    Am J Gastroenterol; 2011 Mar; 106(3):547; author reply 547-8. PubMed ID: 21378771
    [No Abstract]   [Full Text] [Related]  

  • 14. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
    Scaldaferri F; Gerardi V; Mangiola F; Lopetuso LR; Pizzoferrato M; Petito V; Papa A; Stojanovic J; Poscia A; Cammarota G; Gasbarrini A
    World J Gastroenterol; 2016 Jun; 22(24):5505-11. PubMed ID: 27350728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
    Kruis W; Jonaitis L; Pokrotnieks J; Mikhailova TL; Horynski M; Bátovský M; Lozynsky YS; Zakharash Y; Rácz I; Kull K; Vcev A; Faszczyk M; Dilger K; Greinwald R; Mueller R;
    Aliment Pharmacol Ther; 2011 Feb; 33(3):313-22. PubMed ID: 21138455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hair of the dog.
    Bahrani O
    Am J Gastroenterol; 2001 Sep; 96(9):2789-90. PubMed ID: 11569714
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy.
    Yamamoto T; Umegae S; Matsumoto K
    Dig Liver Dis; 2011 May; 43(5):386-90. PubMed ID: 21195041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ulcerative colitis].
    Felley C; Michetti P
    Rev Med Suisse Romande; 2002 Sep; 122(9):441-4. PubMed ID: 12422474
    [No Abstract]   [Full Text] [Related]  

  • 20. [Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease].
    Marteau P; Seksik P
    Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C94-7. PubMed ID: 11787388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.